HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.0184
Abstract: Importance Glioblastoma is an incurable tumor, and the therapeutic options for patients are limited. Objective To determine whether the systemic administration of HER2-specific chimeric antigen receptor (CAR)–modified virus-specific T cells (VSTs) is safe and whether… read more here.
Keywords: her2 car; glioblastoma; her2; virus ... See more keywords
Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer.
Sign Up to like & getrecommendations! Published in 2018 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2017.3323
Abstract: TheAmericanSocietyforClinicalPathologytogetherwith the College of American Pathologists, the Association for Molecular Pathology, and the American Society of Clinical Oncology have recently published a guideline for biomarkers in the evaluation of colorectal cancer (CRC).1 In this article… read more here.
Keywords: biomarker; cancer; metastatic crc; her2 ... See more keywords
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.6012
Abstract: Importance The 2013/2014 American Society of Clinical Oncology and College of American Pathologists (ASCO-CAP) guidelines for HER2 testing by fluorescence in situ hybridization (FISH) designated an “equivocal” category (average HER2 copies per tumor cell ≥4-6… read more here.
Keywords: her2 equivocal; alternative control; breast; breast cancers ... See more keywords
Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2-positive cancers.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13419
Abstract: Human epidermal growth factor receptor 2 (ErbB2/HER2) is a tyrosine kinase receptor that is overexpressed in 25% of primary human breast cancers, as well as in multiple other cancers. HER2-targeted therapies improved progression-free and overall… read more here.
Keywords: ebselen oxide; oxide derivatives; her2; new allosteric ... See more keywords
Enhanced humoral immunity in breast cancer patients with high serum concentration of anti‐HER2 autoantibody
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3742
Abstract: Humoral immunity plays a substantial role in the suppression of breast cancer. We have revealed that a high serum concentration of anti‐HER2 autoantibody (HER2‐AAb) is associated with favorable outcomes in patients with invasive breast cancer.… read more here.
Keywords: her2 aab; her2; breast cancer;
Intratumoral heterogeneity, treatment response, and survival outcome of ER‐positive HER2‐positive breast cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5788
Abstract: ER+HER2+ breast cancer requires most types of systemic therapies perioperatively. However, treatment resistance is often experienced. The current study investigated the predictive and prognostic value of intratumoral heterogeneity and conventional clinicopathological factors in patients with… read more here.
Keywords: her2; breast cancer; treatment; cancer ... See more keywords
Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5817
Abstract: Loss of HER2 “positivity” can occur in patients with residual disease after neoadjuvant treatment, but the incidence of HER2‐positivity loss after neoadjuvant dual HER2‐targeted treatment plus chemotherapy, the current standard‐of‐care for most early stage HER2‐positive… read more here.
Keywords: dual her2; her2; her2 positivity; positivity loss ... See more keywords
A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysis
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34200
Abstract: Small invasive breast cancers (BCs) with tumor sizes ≤5 mm (T1a) are associated with an excellent prognosis without systemic therapy. Although HER2 overexpression (HER2+) is associated with a higher risk of recurrence and poorer clinical… read more here.
Keywords: pt1an0m0; breast; her2; therapy ... See more keywords
Targeted next‐generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance
Sign Up to like & getrecommendations! Published in 2017 at "Genes"
DOI: 10.1002/gcc.22431
Abstract: HER2‐positive breast cancers are a heterogeneous group of tumors, which share amplification and overexpression of HER2. In routine diagnostics, the HER2 (ERBB2) status is currently assessed by immunohistochemistry (IHC) and in situ hybridization (ISH). Data… read more here.
Keywords: status; targeted next; erbb2 status; breast ... See more keywords
Radiomics predicts response of individual HER2‐amplified colorectal cancer liver metastases in patients treated with HER2‐targeted therapy
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Cancer"
DOI: 10.1002/ijc.33271
Abstract: The aim of our study was to develop and validate a machine learning algorithm to predict response of individual HER2‐amplified colorectal cancer liver metastases (lmCRC) undergoing dual HER2‐targeted therapy. Twenty‐four radiomics features were extracted after… read more here.
Keywords: response individual; response; individual her2; cancer ... See more keywords
Breast cancer stem cells are involved in Trastuzumab resistance through the HER2 modulation in 3D culture
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.26298
Abstract: Breast cancer human cells culture as spheroids develop autophagy and apoptosis, which promotes Trastuzumab resistance in HER2 overexpressing cells. Our aim was to study the association of the hostile environment developed in 3D with the… read more here.
Keywords: cancer; her2; cancer stem; breast cancer ... See more keywords